Janelle Zeihen worried she’d have to file for bankruptcy after learning she owed $250,000 for her Crohn’s disease treatment.  The Milwaukee nursing home worker thought her insurance was covering the ...

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a ...

AbbVie Inc. (NYSE:ABBV) reported an earnings per share (EPS) of $2.46, beating the estimated $2.38 and marking a 2.93% ...

Compounding the robust improvements in sales, AbbVie raised its profitability guidance for the full year. It now expects to post adjusted per-share earnings of $12.09 to $12.29; previously it was ...

AbbVie has kicked off the year with a resounding success, exceeding expectations across multiple therapeutic areas. The ...

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie Inc. ABBV reported first-quarter 2025 adjusted earnings per share (EPS) of $2.46, which beat the Zacks Consensus ...

While management did not quantify any potential tariff exposure, it did signal that the effect would be in line with the ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...